GlassScriptPhysician profile
Joseph J Savon
NPI 1285740639
$14,247.87
in general payments reported to CMS, 2019-2025
36 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,663 · 2020: $2,810 · 2021: $1,151 · 2022: $1,264 · 2023: $1,290 · 2024: $1,222 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,329 · Education: $30.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.06 |
| Education | $30.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,643.34 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,703.54 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $552.84 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $396.91 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $352.34 | 2019-2024 | |
| Alkermes, INC. | $281.92 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Janssen Biotech, INC. | $274.39 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $271.92 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $257.72 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $212.02 | 2024-2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $169.71 | 2019-2024 | Sutab, Suflave |
| Braeburn INC. | $145.15 | 2023-2025 | Brixadi |
| Ironwood Pharmaceuticals, INC | $132.41 | 2019-2024 | Linzess |
| Medtronic, INC. | $85.37 | 2022 | |
| Ardelyx, INC. | $82.44 | 2022-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $74.35 | 2023-2025 | |
| Vivus LLC | $60.86 | 2019-2021 | |
| Allergan, INC. | $60.71 | 2019 | |
| Phathom Pharmaceuticals, INC. | $60.00 | 2024-2025 | Voquezna |
| Genzyme Corporation | $56.95 | 2023-2024 | |
| Fresenius Kabi USA, LLC | $49.61 | 2023-2024 | Idacio |
| Ucb, INC. | $41.73 | 2019-2020 | |
| Madrigal Pharmaceuticals | $36.36 | 2025 | Rezdiffra |
| Amgen INC. | $27.80 | 2023 | Avsola |
| Daiichi Sankyo INC. | $26.90 | 2019 | |
| Ferring Pharmaceuticals INC. | $26.89 | 2025 | Rebyota |
| Merck Sharp & Dohme LLC | $25.36 | 2019-2020 | |
| Organon LLC | $19.98 | 2024 | |
| Teleflex LLC | $17.98 | 2024 | Solesta |
| Ge Healthcare | $16.82 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Celltrion USA INC. | $15.72 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $14.04 | 2023 | Movantik, Talicia, Aemcolo |
| Intercept Pharmaceuticals, INC. | $14.02 | 2020 | |
| Shire North American Group INC | $13.66 | 2019 | |
| Erbe USA INC | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Savon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.